BioRestorative Therapies Company Insiders
| BRTX Stock | USD 1.52 0.10 6.17% |
BioRestorative Therapies employs about 11 people. The company is managed by 6 executives with a total tenure of roughly 26 years, averaging almost 4.0 years of service per executive, having 1.83 employees per reported executive. Break down of BioRestorative Therapies' management performance can provide insight into the company performance.
BioRestorative |
BioRestorative Therapies Management Team Effectiveness
The company has return on total asset (ROA) of (0.5324) % which means that it has lost $0.5324 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8456) %, meaning that it created substantial loss on money invested by shareholders. BioRestorative Therapies' management efficiency ratios could be used to measure how well BioRestorative Therapies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.83 in 2025. Return On Capital Employed is likely to rise to -1.66 in 2025. At this time, BioRestorative Therapies' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 368.6 K in 2025, whereas Non Current Assets Total are likely to drop slightly above 1.3 M in 2025.Common Stock Shares Outstanding is likely to rise to about 5.1 M in 2025, whereas Net Loss is likely to drop (17.5 M) in 2025.
BioRestorative Therapies Workforce Comparison
BioRestorative Therapies is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 407. BioRestorative Therapies holds roughly 11.0 in number of employees claiming about 2.7% of equities under Health Care industry.
BioRestorative Therapies Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioRestorative Therapies insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioRestorative Therapies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, BioRestorative Therapies insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioRestorative Therapies Notable Stakeholders
A BioRestorative Therapies stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BioRestorative Therapies often face trade-offs trying to please all of them. BioRestorative Therapies' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BioRestorative Therapies' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Lance Alstodt | President Board | Profile | |
| Francisco Silva | VP Scientist | Profile | |
| Robert Paccasassi | Vice Compliance | Profile | |
| Stephen Kilmer | Investor Officer | Profile | |
| Wayne MD | Clinical Board | Profile | |
| Robert Kristal | Chief Officer | Profile |
About BioRestorative Therapies Management Performance
The success or failure of an entity such as BioRestorative Therapies often depends on how effective the management is. BioRestorative Therapies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioRestorative management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioRestorative management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.79) | (0.83) | |
| Return On Capital Employed | (1.75) | (1.66) | |
| Return On Assets | (0.74) | (0.78) | |
| Return On Equity | (1.20) | (1.14) |
Please note, the imprecision that can be found in BioRestorative Therapies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioRestorative Therapies. Check BioRestorative Therapies' Beneish M Score to see the likelihood of BioRestorative Therapies' management manipulating its earnings.
BioRestorative Therapies Workforce Analysis
Traditionally, organizations such as BioRestorative Therapies use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BioRestorative Therapies within its industry.BioRestorative Therapies Manpower Efficiency
Return on BioRestorative Therapies Manpower
| Revenue Per Employee | 13.3K | |
| Revenue Per Executive | 24.3K | |
| Net Loss Per Employee | 947.1K | |
| Net Loss Per Executive | 1.7M | |
| Working Capital Per Employee | 798.5K | |
| Working Capital Per Executive | 1.5M |
Additional Tools for BioRestorative Stock Analysis
When running BioRestorative Therapies' price analysis, check to measure BioRestorative Therapies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioRestorative Therapies is operating at the current time. Most of BioRestorative Therapies' value examination focuses on studying past and present price action to predict the probability of BioRestorative Therapies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioRestorative Therapies' price. Additionally, you may evaluate how the addition of BioRestorative Therapies to your portfolios can decrease your overall portfolio volatility.